Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Pediatr Gastroenterol Nutr ; 31(5): 540-53, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11144440

ABSTRACT

BACKGROUND: In contrast to human milk, current infant formulas in the United States do not contain omega3 and omega6 long-chain polyunsaturated fatty acids. This may lead to suboptimal blood lipid fatty acid profiles and to a measurable diminution of visual function in developing term infants. The need for docosahexaenoic acid and arachidonic acid supplementation in the infant diet was evaluated in a double-blind, randomized clinical trial. METHODS: Healthy term infants were randomized to diets of (1) commercial formula, (2) docosahexaenoic acid-enriched formula (0.35% of total fatty acids), or (3) docosahexaenoic acid- (0.36%) and arachidonic acid- (0.72%) enriched formula. Eighty-seven infants completed the 17-week nutritional trial, and 58 were observed until 52 weeks of life. A reference group was exclusively breast fed for at least 17 weeks (n = 29). Outcome measures included electroretinographic responses, visual evoked potentials, and blood fatty acid analysis in infants at birth and at 6, 17, and 52 weeks of age. RESULTS: Commercial formula-fed infants had 30% to 50% lower content of docosahexaenoic acid in total red blood cell lipids during the 17-week feeding trial compared with breastfed infants. Significant differences persisted at the 1-year follow-up. Arachidonic acid content was consistently reduced in the commercial formula group by 15% to 20%. Infants fed long-chain polyunsaturated fatty acid-enriched formulas had docosahexaenoic acid and arachidonic acid blood lipid profiles resembling those of human milk-fed infants. Infants receiving this enriched formula had more mature electroretinographic responses than commercial formula-fed infants at 6 weeks of age. Human milk-fed and docosahexaenoic acid-enriched formula-fed infants had better visual acuity than commercial formula-fed infants at both 17 and 52 weeks of age. Early (17-week) fatty acid profiles in blood lipids were correlated with later (52-week) visual function development in study infants. CONCLUSIONS: Results from this clinical trial demonstrate that long-chain polyunsaturated fatty acid supplementation of formula in term infants produces blood lipid fatty acid profiles that are similar to those observed in breast-fed infants. This supplementation leads to better visual function later in life (i.e., 1 year of age) than that shown by infants fed commercial formula.


Subject(s)
Arachidonic Acid/pharmacology , Docosahexaenoic Acids/pharmacology , Evoked Potentials, Visual/drug effects , Fatty Acids/blood , Infant Food , Visual Acuity/drug effects , Arachidonic Acid/administration & dosage , Arachidonic Acid/blood , Bottle Feeding , Breast Feeding , Cohort Studies , Docosahexaenoic Acids/administration & dosage , Docosahexaenoic Acids/blood , Double-Blind Method , Electroretinography , Erythrocytes/chemistry , Evoked Potentials, Visual/physiology , Fatty Acids/analysis , Fatty Acids, Omega-3/administration & dosage , Fatty Acids, Omega-3/analysis , Fatty Acids, Omega-6 , Fatty Acids, Unsaturated/administration & dosage , Fatty Acids, Unsaturated/analysis , Female , Fetal Blood/chemistry , Humans , Infant , Infant Food/analysis , Infant Nutritional Physiological Phenomena , Infant, Newborn , Lipids/blood , Lipids/chemistry , Retina/drug effects , Retina/physiology , Visual Acuity/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...